Hexagonal biotechnology companies experienced an exceptional year with the start-up sector, with a 50% increase in one-year fundraisers, a record amount of 2.3 billion euros. .
by
This is a great performance for the French “Health Tech”. While Aelis Farma, a Bordeaux company specializing in the development of treatments against cognitive impairment, is preparing to open this week the ball of the Biotech Stock Exchange introductions on the European market for 2022, the tricolore sector has drawn up on Tuesday 15 February, a very strong balance sheet 2021.
Young shoots in the sector, which include biotechs, medical device manufacturers or digital health and diagnosis specialists, lifted a record amount of 2.3 billion euros in 2021, or 50% Moreover, the previous year, according to the panorama published by the association France Biotech. “A CAP in the development of our ecosystem has certainly been crossed during this year. To us to anchor this dynamic and demonstrate that France has a very strong card to play in health innovation,” rejoices Franck Mouthon, his president.
Among the emblematic fundraisers the year 2021 are included in particular that of the Francilien Dna Script, who signed a rider at 172 million euros, or of Dental Monitoring (129 million euros), – first times that high white white start-ups cross the threshold of 100 million euros on a lifting – but also from Mnemo Therapeutics (75 million euros), from Treefrog Therapeutics (64 million euros) or from Tissium (50 million euros).
Maturity gain
The sector, which has about 2,000 companies in the hex, realizes a modest turnover (800 million euros in 2020), but the French nuggets of health earn in maturity. Drugs and treatments currently tested by biotechs at advanced phase 2 or 3 clinical stages now account for 47% of the development programs recorded within the sector. On the side of the manufacturers of medical devices (implants, prostheses, scanners …), the number of products marketed has, on the other hand, climbed a quarter over one year.
This beautiful performance is not the prerogative of the only France. Europe, in general, benefited from a renewed interest of investors for health innovations. Of the 55 billion euros lifted around the world in 2021 by the companies of the “Health Tech”, 17.5 billion concerned European companies. An amount that has more than quadrupled in five years. “There is a real catch-up of the funding of European societies, with some table towers to more than 200 million euros that look a little more like those that can be seen in the United States,” said Cédric Garcia, associated with the within the cabinet EY. The latter emphasizes the dynamism of European investment funds, like Jeito Capital, Sofinnova or Life Science Partners (LSP), whose funding capabilities have been largely expanded in recent months.
You have 13.83% of this article to read. The rest is reserved for subscribers.